Venofer
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease. It is administered intravenously and is dissociated into iron and sucrose once in circulation. The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell.
TABLE OF CONTENTS
4 Product Profiles
4 Venofer : Anemia in chronic kidney disease
LIST OF FIGURES
9 Figure 1: Venofer for anemia in chronic kidney disease – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Venofer for anemia in chronic kidney disease
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Venofer for anemia in chronic kidney disease
13 Figure 4: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
LIST OF TABLES
5 Table 1: Venofer drug profile
6 Table 2: Venofer pivotal trial data in anemia in chronic kidney disease
8 Table 3: Venofer late-phase trial data in anemia in chronic kidney disease
14 Table 4: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Epogen 
Sign up to the